October 15, 2013

Helix BioPharma Corp. Completes Data Review of First Four Cohorts of its Phase I/II Clinical Study for Lung Cancer Drug Candidate L-DOS47 (PDF)

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has completed its interim review of the Company’s ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland (the “LDOS002 Study”). This review was not a formal analysis of data, but a review of safety and clinical parameters collected during the study to date.